Aesthetic Injectables Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Aesthetic Injectables Pipeline Market Report Overview

Aesthetic Injectables refer to gel-like substances that are injected beneath the skin to restore a more youthful appearance. This is achieved by increasing the volume of sunken cheeks or temples, reducing lines around nose and mouth (marionette lines and smile lines), plumping up lips and enhancing facial contour. The Aesthetic Injectables pipeline market research report provides comprehensive information about the aesthetic Injectables pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Key Segments ·       Hyaluronic Acid Fillers

·       Non-Hyaluronic Acid Fillers

·       Biphasic Hyaluronic Acid Fillers

·       Poly-L-Lactic Acid (PLLA) Fillers

Key Territories ·       United States

·       Europe

·       China

·       South Korea

·       Others

Key Regulatory Paths ·       PMA

·       CE

·       NMPA

·       NIFDS

·       510(k)

·       BOPA

·       HSA

·       MDITAC

·       MDL

·       MDCO

·       ANVISA

·       ICAC

·       MDA

·       Ninsho

·       TGA

·       Shonin

Leading Companies ·       AbbVie Inc

·       BioPlus Co Ltd

·       Celltrix AB

·       Galderma SA

·       Others

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Aesthetic Injectables Pipeline Market Segments

Some of the key segments in the aesthetic Injectables pipeline market are Hyaluronic Acid Fillers, Non-Hyaluronic Acid Fillers, Biphasic Hyaluronic Acid Fillers, and Poly-L-Lactic Acid (PLLA) Fillers. As of May 2023, Hyaluronic Acid Fillers had the highest share.

Aesthetic Injectables Pipeline Market Analysis, by Segments, 2023 (%)

Aesthetic Injectables Pipeline Market Analysis, by Segments, 2023 (%)

For more segment insights into the aesthetic Injectables pipeline market, download a free report sample

Aesthetic Injectables Pipeline Market Segmentation by Territories

Some key territories with aesthetic Injectables products in the pipeline are the US, Europe, China, South Korea, Israel, and Taiwan among others. As of May 2023, the US had the highest number of products in the pipeline compared to the other territories.

Aesthetic Injectables Pipeline Market Analysis, by Territories, 2023 (%)

Aesthetic Injectables Pipeline Market Analysis, by Territories, 2023 (%)

For more territory insights into the aesthetic Injectables pipeline market, download a free report sample

Aesthetic Injectables Pipeline Market Segmentation by Regulatory Paths

Some of the key regulatory paths followed by the aesthetic Injectables pipeline products are PMA, CE, NMPA, NIFDS, 510 (k), BOPA, HAS, MDITAC, and MDL among others.  As of May 2023, the mostly deployed regulatory path for aesthetic Injectables market was PMA.

Aesthetic Injectables Pipeline Market Analysis, by Regulatory Paths, 2023 (%)

Aesthetic Injectables Pipeline Market Analysis, by Regulatory Paths, 2023 (%)

For more regulatory path insights into the Aesthetic Injectables pipeline market, download a free report sample

Aesthetic Injectables Pipeline Market – Competitive Landscape

Some of the leading companies in the Aesthetic Injectables pipeline reconstruction market are AbbVie Inc, BioPlus Co Ltd, Celltrix AB, Galderma SA, Genzyme Corp, Medytox Inc, Teoxane SA, and Tissueform Inc among others.

AbbVie Inc Overview: AbbVie Inc (AbbVie) is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn’s disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn’s disease, Parkinson’s disease, viral diseases, wet AMD, various cancers, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.

Segments Covered in the Report

Aesthetic Injectables Pipeline Market Segments Outlook

  • Hyaluronic Acid Fillers
  • Non-Hyaluronic Acid Fillers
  • Biphasic Hyaluronic Acid Fillers
  • Poly-L-Lactic Acid (PLLA) Fillers

Aesthetic Injectables Pipeline Market Territories Outlook

  • United States
  • Europe
  • China
  • South Korea
  • Global
  • Israel
  • Taiwan
  • Singapore
  • Vietnam
  • Canada
  • Japan
  • Hong Kong
  • Australia
  • Brazil
  • India
  • Malaysia
  • New Zealand
  • Philippines
  • Russia
  • Germany
  • Mexico
  • Indonesia
  • Egypt
  • Turkey

Aesthetic Injectables Pipeline Market Regulatory Paths Outlook

  • PMA
  • CE
  • NMPA
  • NIFDS
  • 510(k)
  • BOPA
  • HSA
  • MDITAC
  • MDL
  • MDCO
  • ANVISA
  • ICAC
  • MDA
  • Ninsho
  • TGA
  • Shonin

Scope

  • Extensive coverage of the Aesthetic Injectables under development
  • Reviews details of major pipeline reconstruction which include, product description, licensing and collaboration details, and other developmental activities
  • Reviews the major players involved in the development of Aesthetic Injectables and list all their pipeline projects
  • The coverage of pipeline reconstruction based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry

Reasons to Buy

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage
  • Identify and understand important and diverse types of Aesthetic Injectables under development
  • Develop market-entry and market-expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory, and estimated launch date

AbbVie Inc
Acro Biomedical Co Ltd
Advanced Aesthetic Technologies Inc
Aeon Astron Corporation
Aesthetic Medical Device
Allergan Aesthetics
Almirall Ltd
Beijing MeiYan KongJian Technology Co Ltd
BioPlus Co Ltd
Bioxis Pharmaceuticals
BMG Pharma SpA
Bmi Korea Co Ltd
CellPraxis
Celltrix AB
Collplant Biotechnologies Ltd
Dexlevo Inc
Dongkook Pharmaceutical Co Ltd
EternoGen Aesthetics LLC
Fillmed Laboratoires
G2GBIO Inc
Galderma SA
Genzyme Corp
Hallura Ltd
Histogen Inc
Hugel Inc
Innovia LLC
inSoma Bio Inc
Inventage Lab Inc
Jinwoo Bio Co Ltd
Juvenis Ltd
Khorionyx SA
Laboratoires Vivacy SAS
LG Chem Ltd
LifeSprout Inc
Medytox Inc
Merz North America Inc
Mesoestetic Pharma Group SL
Moma Therapeutics Inc
N8 Medical LLC
Oligo Medic Inc
PB&B SA
Peptron Inc
PetVivo Holdings Inc
Q-Med AB
RepliCel Life Sciences Inc
Samyang Biopharmaceuticals Corp
Sebana Medical Ltd
Shanghai Haohai Biological Technology Co Ltd
Shin Poong Pharm Co Ltd
Silk Medical Aesthetics Inc
Sinclair Pharma Ltd
Sofregen Medical Inc
SunMax Biotechnology Co Ltd
TEI Biosciences Inc
Tempo Therapeutics Inc
Teoxane SA
Tetratherix Pty Ltd
Tissueform Inc
University of California Santa Barbara
University of Missouri

Table of Contents

|1 Table of Contents 3

|1.1 List of Tables 6

|1.2 List of Figures 13

2 Introduction 14

2.1 Aesthetic Injectables Overview 14

3 Products under Development 15

3.1 Aesthetic Injectables – Pipeline Products by Stage of Development 15

3.2 Aesthetic Injectables – Pipeline Products by Segment 16

3.3 Aesthetic Injectables – Pipeline Products by Territory 17

3.4 Aesthetic Injectables – Pipeline Products by Regulatory Path 19

3.5 Aesthetic Injectables – Pipeline Products by Estimated Approval Date 20

3.6 Aesthetic Injectables – Ongoing Clinical Trials 21

4 Aesthetic Injectables – Pipeline Products under Development by Companies 22

4.1 Aesthetic Injectables Companies – Pipeline Products by Stage of Development 22

4.2 Aesthetic Injectables – Pipeline Products by Stage of Development 25

5 Aesthetic Injectables Companies and Product Overview 28

5.1 AbbVie Inc Company Overview 28

5.1.1 AbbVie Inc Pipeline Products & Ongoing Clinical Trials Overview 28

5.2 Acro Biomedical Co Ltd Company Overview 29

5.2.1 Acro Biomedical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 29

5.3 Advanced Aesthetic Technologies Inc Company Overview 30

5.3.1 Advanced Aesthetic Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 30

5.4 Aeon Astron Corporation Company Overview 35

5.4.1 Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview 35

5.5 Aesthetic Medical Device Company Overview 36

5.5.1 Aesthetic Medical Device Pipeline Products & Ongoing Clinical Trials Overview 36

5.6 Allergan Aesthetics Company Overview 39

5.6.1 Allergan Aesthetics Pipeline Products & Ongoing Clinical Trials Overview 39

5.7 Almirall Ltd Company Overview 51

5.7.1 Almirall Ltd Pipeline Products & Ongoing Clinical Trials Overview 51

5.8 Beijing MeiYan KongJian Technology Co Ltd Company Overview 52

5.8.1 Beijing MeiYan KongJian Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 52

5.9 BioPlus Co Ltd Company Overview 55

5.9.1 BioPlus Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 55

5.10 Bioxis Pharmaceuticals Company Overview 58

5.10.1 Bioxis Pharmaceuticals Pipeline Products & Ongoing Clinical Trials Overview 58

5.11 BMG Pharma SpA Company Overview 61

5.11.1 BMG Pharma SpA Pipeline Products & Ongoing Clinical Trials Overview 61

5.12 Bmi Korea Co Ltd Company Overview 63

5.12.1 Bmi Korea Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 63

5.13 CellPraxis Company Overview 64

5.13.1 CellPraxis Pipeline Products & Ongoing Clinical Trials Overview 64

5.14 Celltrix AB Company Overview 65

5.14.1 Celltrix AB Pipeline Products & Ongoing Clinical Trials Overview 65

5.15 Collplant Biotechnologies Ltd Company Overview 66

5.15.1 Collplant Biotechnologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 66

5.16 Dexlevo Inc Company Overview 68

5.16.1 Dexlevo Inc Pipeline Products & Ongoing Clinical Trials Overview 68

5.17 Dongkook Pharmaceutical Co Ltd Company Overview 69

5.17.1 Dongkook Pharmaceutical Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 69

5.18 EternoGen Aesthetics LLC Company Overview 72

5.18.1 EternoGen Aesthetics LLC Pipeline Products & Ongoing Clinical Trials Overview 72

5.19 Fillmed Laboratoires Company Overview 73

5.19.1 Fillmed Laboratoires Pipeline Products & Ongoing Clinical Trials Overview 73

5.20 G2GBIO Inc Company Overview 75

5.20.1 G2GBIO Inc Pipeline Products & Ongoing Clinical Trials Overview 75

5.21 Galderma SA Company Overview 76

5.21.1 Galderma SA Pipeline Products & Ongoing Clinical Trials Overview 76

5.22 Genzyme Corp Company Overview 77

5.22.1 Genzyme Corp Pipeline Products & Ongoing Clinical Trials Overview 77

5.23 Hallura Ltd Company Overview 78

5.23.1 Hallura Ltd Pipeline Products & Ongoing Clinical Trials Overview 78

5.24 Histogen Inc Company Overview 80

5.24.1 Histogen Inc Pipeline Products & Ongoing Clinical Trials Overview 80

5.25 Hugel Inc Company Overview 81

5.25.1 Hugel Inc Pipeline Products & Ongoing Clinical Trials Overview 81

5.26 Innovia LLC Company Overview 85

5.26.1 Innovia LLC Pipeline Products & Ongoing Clinical Trials Overview 85

5.27 inSoma Bio Inc Company Overview 86

5.27.1 inSoma Bio Inc Pipeline Products & Ongoing Clinical Trials Overview 86

5.28 Inventage Lab Inc Company Overview 87

5.28.1 Inventage Lab Inc Pipeline Products & Ongoing Clinical Trials Overview 87

5.29 Jinwoo Bio Co Ltd Company Overview 90

5.29.1 Jinwoo Bio Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 90

5.30 Juvenis Ltd Company Overview 93

5.30.1 Juvenis Ltd Pipeline Products & Ongoing Clinical Trials Overview 93

5.31 Khorionyx SA Company Overview 94

5.31.1 Khorionyx SA Pipeline Products & Ongoing Clinical Trials Overview 94

5.32 Laboratoires Vivacy SAS Company Overview 95

5.32.1 Laboratoires Vivacy SAS Pipeline Products & Ongoing Clinical Trials Overview 95

5.33 LG Chem Ltd Company Overview 98

5.33.1 LG Chem Ltd Pipeline Products & Ongoing Clinical Trials Overview 98

5.34 LifeSprout Inc Company Overview 107

5.34.1 LifeSprout Inc Pipeline Products & Ongoing Clinical Trials Overview 107

5.35 Medytox Inc Company Overview 110

5.35.1 Medytox Inc Pipeline Products & Ongoing Clinical Trials Overview 110

5.36 Merz North America Inc Company Overview 113

5.36.1 Merz North America Inc Pipeline Products & Ongoing Clinical Trials Overview 113

5.37 Mesoestetic Pharma Group SL Company Overview 116

5.37.1 Mesoestetic Pharma Group SL Pipeline Products & Ongoing Clinical Trials Overview 116

5.38 Moma Therapeutics Inc Company Overview 120

5.38.1 Moma Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 120

5.39 N8 Medical LLC Company Overview 121

5.39.1 N8 Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 121

5.40 Oligo Medic Inc Company Overview 122

5.40.1 Oligo Medic Inc Pipeline Products & Ongoing Clinical Trials Overview 122

5.41 PB&B SA Company Overview 123

5.41.1 PB&B SA Pipeline Products & Ongoing Clinical Trials Overview 123

5.42 Peptron Inc Company Overview 124

5.42.1 Peptron Inc Pipeline Products & Ongoing Clinical Trials Overview 124

5.43 PetVivo Holdings Inc Company Overview 125

5.43.1 PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 125

5.44 Q-Med AB Company Overview 127

5.44.1 Q-Med AB Pipeline Products & Ongoing Clinical Trials Overview 127

5.45 RepliCel Life Sciences Inc Company Overview 132

5.45.1 RepliCel Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 132

5.46 Samyang Biopharmaceuticals Corp Company Overview 133

5.46.1 Samyang Biopharmaceuticals Corp Pipeline Products & Ongoing Clinical Trials Overview 133

5.47 Sebana Medical Ltd Company Overview 135

5.47.1 Sebana Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview 135

5.48 Shanghai Haohai Biological Technology Co Ltd Company Overview 136

5.48.1 Shanghai Haohai Biological Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 136

5.49 Shin Poong Pharm Co Ltd Company Overview 138

5.49.1 Shin Poong Pharm Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 138

5.50 Silk Medical Aesthetics Inc Company Overview 139

5.50.1 Silk Medical Aesthetics Inc Pipeline Products & Ongoing Clinical Trials Overview 139

5.51 Sinclair Pharma Ltd Company Overview 143

5.51.1 Sinclair Pharma Ltd Pipeline Products & Ongoing Clinical Trials Overview 143

5.52 Sofregen Medical Inc Company Overview 147

5.52.1 Sofregen Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 147

5.53 SunMax Biotechnology Co Ltd Company Overview 150

5.53.1 SunMax Biotechnology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 150

5.54 TEI Biosciences Inc Company Overview 155

5.54.1 TEI Biosciences Inc Pipeline Products & Ongoing Clinical Trials Overview 155

5.55 Tempo Therapeutics Inc Company Overview 156

5.55.1 Tempo Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 156

5.56 Teoxane SA Company Overview 157

5.56.1 Teoxane SA Pipeline Products & Ongoing Clinical Trials Overview 157

5.57 Tetratherix Pty Ltd Company Overview 161

5.57.1 Tetratherix Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 161

5.58 Tissueform Inc Company Overview 162

5.58.1 Tissueform Inc Pipeline Products & Ongoing Clinical Trials Overview 162

5.59 University of California Santa Barbara Company Overview 163

5.59.1 University of California Santa Barbara Pipeline Products & Ongoing Clinical Trials Overview 163

5.60 University of Missouri Company Overview 164

5.60.1 University of Missouri Pipeline Products & Ongoing Clinical Trials Overview 164

6 Aesthetic Injectables- Recent Developments 165

6.1 Dec 16, 2022: MOXI and BBL treatments are now available at Chapin Aesthetics 165

7 Appendix 166

7.1 Methodology 166

7.2 About GlobalData 169

7.3 Contact Us 169

7.4 Disclaimer 169

Frequently asked questions

Aesthetic Injectables Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies thematic reports
Currency USD
$4,000

Can be used by individual purchaser only

$12,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Aesthetic Injectables Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Aesthetic Injectables Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies in real time.

  • Access a live Aesthetic Injectables Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.